Preservation of renal function in cardiac surgery patients with low cardiac output syndrome: levosimendan vs beta agonists

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN46058317

Enrollment

100

Registered

2019-10-07

Start date

2015-02-01

Completion date

Unknown

Last updated

2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low cardiac output syndrome (LCOS) Circulatory System

Interventions

It was a quasi-experiment study used to estimate the causal impact of an intervention on the target population without random assignment. Quasi-experimental research shares similarities with the tradi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients older than 18 years who developed postoperative low cardiac output syndrome (LCOS) following heart surgery 2. LCOS (was defined as: a cardiac index < 2l/min/m2, or central venous saturation <65% after volume replacement) . It was checked by echocardiogram and Mostcare® (continuous cardiac index monitoring) 3. Patients who required inotropic support for the treatment of LCOS

Exclusion criteria

Exclusion criteria: 1. Patients who required combined surgery (not only cardiac surgery) 2. Emergency surgery 3. Preoperative diagnosis of chronic kidney failure

Design outcomes

Primary

Measure	Time frame
Renal function parameters: 1. Creatinine measured using ELISA at baseline, 24 and 48 hours and ICU discharge 2. Stage of renal failure measured by the Acute renal failure (AKI) scale at baseline, 24 and 48 hours and ICU discharge 3. Diuresis and use of diuretics (mg of furosemide) measured using diuresis output at baseline, 24 and 48 hours and ICU discharge 4. Requirement of renal replacement therapy measured using dialysis therapy at ICU discharge	—

Measure

Time frame

Renal function parameters: 1. Creatinine measured using ELISA at baseline, 24 and 48 hours and ICU discharge 2. Stage of renal failure measured by the Acute renal failure (AKI) scale at baseline, 24 and 48 hours and ICU discharge 3. Diuresis and use of diuretics (mg of furosemide) measured using diuresis output at baseline, 24 and 48 hours and ICU discharge 4. Requirement of renal replacement therapy measured using dialysis therapy at ICU discharge

—

Secondary

Measure	Time frame
Hemodynamics: 1. HR (arrhythmia de novo) measured using EKG at baseline, 24 and 48 hours and ICU discharge 2. Multifocal atrial tachycardia (MAT) measured using EKG at baseline, 24 and 48 hours and ICU discharge 3. Heart failure (HF) measured using locs definition at baseline, 24 and 48 hours and ICU discharge 4. Ejection fraction of the left ventricle (EFLV) measured using Echo at baseline, 24 and 48 hours and ICU discharge 5. SvcO2 measured using oximetry at baseline, 24 and 48 hours and ICU discharge 6. Central venous pressure (CVP) measured using pressure transductor at baseline, 24 and 48 hours and ICU discharge	—

Measure

Time frame

Hemodynamics: 1. HR (arrhythmia de novo) measured using EKG at baseline, 24 and 48 hours and ICU discharge 2. Multifocal atrial tachycardia (MAT) measured using EKG at baseline, 24 and 48 hours and ICU discharge 3. Heart failure (HF) measured using locs definition at baseline, 24 and 48 hours and ICU discharge 4. Ejection fraction of the left ventricle (EFLV) measured using Echo at baseline, 24 and 48 hours and ICU discharge 5. SvcO2 measured using oximetry at baseline, 24 and 48 hours and ICU discharge 6. Central venous pressure (CVP) measured using pressure transductor at baseline, 24 and 48 hours and ICU discharge

—

Countries

Spain

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026